1096513 EFIB 2018 Start-up-Village Broschur · 2019-07-29 · Organised by Start-up Village @EFIB...

Organised by

Start-up Village@EFIB 2018

16–18 Oct 2018Toulouse, France

#EFIB2018

Supporting Partner Local Partner

Imprint

Publisher

BIOCOM AG

Lützowstr. 33–36

10785 Berlin

www.biocom.de

Layout

Benjamin Röbig

Editorial Team

Annika Rudat

Sandra Wirsching

Illustration

wowomnom/istockphoto.com

The profiles have been provided by the companies and organizations. BIOCOM makes no guarantee for the

content. The publication is available free of charge and part of the Start-up Village communication during the

“European Forum for Industrial Biotechnology and the Bioeconomy” to be held in Toulouse, France, 16–18

October 2018. The event is organized by EuropaBio together with the support of BIOCOM AG and Toulouse

White Biotechnology as local partner. (www.efibforum.com) All rights reserved.

This is a CO2-neutral publication.

About the Start-up Village @EFIB

For the first time, the START-UP VILLAGE @EFIB offers young founders who are active in industrial biotechnology and bioeconomy strong visibility among the international EFIB at-tendees, representing sector stakeholders from companies, academics, SMEs, investors, policy makers, NGOs and media.

The START-UP VILLAGE@EFIB is a new central meeting point, bringing together innovative young businesses with investors as well as industrial corporations.

The Start-up Village represents companies from the following areas:

Textiles Cosmetics Bio-based Materials

Food & Nutrition

Agriculture & Forestry

Bio-based Chemicals

EUROPEAN MARINE BIOLOGICALRESEARCH INFRASTRUCTURE CLUSTER

WE THANK OUR PARTNERS

Content

Networking Partners

BASF Venture Capital ............................... 9

Capricorn Venture Partners ..................... 9

EMBRIC ..................................................... 7

Evonik Venture Capital ........................... 10

Novozymes A/S ........................................ 8

Sofinnova Partners ................................. 10

Toulouse Métropole ................................. 6

Toulouse White Biotechnology ................ 6

Start-up Profiles

Abolis Biotechnology .............................. 12

Algae Natural Food ................................ 13

Algaepro AS ............................................ 14

Arbiom .................................................... 15

b.fab GmbH ............................................ 16

BES Europe Ltd. ...................................... 17

BioBTX B.V. ............................................. 18

Biotech Fine Chemical France ............... 19

BlueGene Technologies Ltd. .................. 20

Cambridge Glycoscience Inc. ................ 21

Chromologics ......................................... 22

Delft Advanced Biorenewables (DAB) .. 23

Enantis s.r.o. ........................................... 24

Evologic Technologies ........................... 25

Green Spot Technologies ...................... 26

Hoekmine B.V. ........................................ 27

Holiferm Ltd. ........................................... 28

iMEAN ..................................................... 29

Kaffe Bueno ApS. ................................... 30

Mosspiration Biotech IVS ....................... 31

PHYTOLINC ............................................ 32

PILI Inc. ................................................... 33

Plantics B.V. ............................................ 34

SilicoLife Lda. ......................................... 35

Networking Partners

6

CONTACT

General aim of the consortiumToulouse White Biotechnology (TWB) is a French pre-industrial demonstrator hosted by INRA (Institut National de Recherche Agronomique) that serves as a national and European focal point for industrial biotechnology, notably by facilitating collaboration between industrial com-panies and academic laboratories. TWB relies on a joint public-private consortium that brings together 46 private and public partners. TWB’s objective is to accelerate development and opti-misation of new bio-processes by providing scientific and technical assistance to industries and promoting market pull research, in relevant sectors (biomass, energy, biomaterial, fine chemis-try, cosmetics…). TWB also supports start-ups by hosting them and by providing workspace and a range of scientific, technological and administrative services.

Profile of partners involvedThe TWB consortium currently includes 30 companies (from start-up to large company), 4 in-vestors, 3 tech transfer partners and 9 public partners including the 3 administrative bodies of TWB (INRA, INSA, CNRS).

Toulouse White Biotechnology

Toulouse Métropole is the métropole, an intercommunal structure, centred on the city of Tou-louse. It is located in the Haute-Garonne department, in the Occitanie region, southern France. It was created in January 2015, replacing the previous Communauté urbaine de Toulouse.

François DelplaProject Manager · [email protected]

CONTACT

Laurie ReyBusiness Development · [email protected]

Toulouse Métropole

7

CONTACT

General aim of the consortiumThe European Marine Biological Research Infrastructure Cluster (EMBRIC) is designed to accel-erate the pace of scientific discovery and innovation from marine bio-resources. EMBRIC aims to promote new applications derived from marine organisms in fields such as drug discovery, aquaculture selective breeding and cosmetics and bioenergy. At the same time, EMBRIC tries to facilitate technology and knowledge transfer and provides access to its various infrastructures to foster innovation in marine biotechnology and promote the blue bioeconomy.

Profile of partners involvedThe EMBRIC consortium connects six existing European Research Infrastructures. This includes:

– the four ESFRI Research Infrastructures (EMBRC, MIRRI, EU-OPENSCREEN, ELIXIR) – and two Integrating Activity projects (AQUAEXCEL and RISIS).

Furthermore, the consortium comprises a total of 29 partners of four different types of stake-holders (academia, research institutes, non-for-profit organizations and industry). EMBRIC partners are distributed in eight EU member states and two associated member states. The countries represented are UK (7 partners), France (6 partners), Germany (5 partners), Norway (3 partners), Italy (2 partners), Spain (2 partners), Portugal (1 partner), Belgium (1 partner), Greece (1 partner), and Israel (1 partner). 17 of the 29 partner institutes are located in peripheral mari-time region. EMBRIC actively supports blue bioeconomy start-ups by offering sponsored transnational ac-cess to research laboratories of renowned institutes of affiliated research infrastructures all over Europe. The access includes technical and scientific support, free use of the services and platforms, and hands-on training to use the facilities. Further, EMBRIC has established discov-ery pipelines for marine bio-products to help scientists from academia and industry on their experimental design and workflow. Company fora on aquaculture and microalgae have been established to support with biological and computational resources, maturation of new tech-nologies, knowledge and training.

EMBRIC

[email protected]

EUROPEAN MARINE BIOLOGICALRESEARCH INFRASTRUCTURE CLUSTER

8

CONTACT

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet’s resourc-es and helping build better lives. As the world’s largest provider of enzyme and microbial tech-nologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.

Specific areas of interest we have• Agri and food tech space, especially biological solutions for control and yield, food protec-

tion, alternative proteins• Pre- & probiotics and other bioactives for human and animal consumption• Companies looking for technology partners for scale-up, optimization & commercialization• In general, we’re open for technology players in every stage if the idea is good

About the “Hello Science” PlattformHelloScience is a platform for helping bright ideas to get to the next level. Get your ideas off the ground, receive global attention and access to technology and knowledge from Novozymes and other partners with no strings attached. We know that alone we don’t hold all the answers and we hope to find partners who share our ambition and passion for technology.

Novozymes A/S

Anuj DhariwalHead of Scouting, Exploration and Minority Investments · [email protected]

Alexander Moldt NielsenNew Business Development · [email protected]

9

CONTACT

BASF Venture Capital GmbH (BVC) was founded in 2001 and has offices in Europe, the U.S., China and Israel. The aim of BVC is to generate new growth potential for BASF by investing in new companies and funds. The focus of investment is on chemical products, incl. biochemicals and new materials, software and services, as well as innovative and digital business models in the broader field of chemistry. BVC’s evergreen fund has a size of EUR 175 m.

Investment focus: Besides the traditional business fields of BASF, additional areas of focus are industrial biotech, new materials, agtech, digitization and new business models.

Jos B. PeetersManaging Director · [email protected]

BASF Venture Capital

CONTACT

Michael-Jean NettersheimInvestment Manager · [email protected]

Capricorn Venture Partners

Capricorn Venture Partners, founded in 1993, is an independent European manager of venture capital and equity funds, investing in innovative companies with technology as competitive advantage. It is currently managing its Capricorn Sustainable Chemistry Fund, Capricorn ICT Arkiv Fund, Capricorn Health-tech Fund and Capricorn Cleantech Fund, is the management company of Quest for Growth, quoted on Euronext Brussels, and invest-ment manager to the Quest Cleantech and Quest+ funds.

Investment focus: We focus on companies with technology as competitive advantage in strategic areas of ICT, Healthtech and Cleantech. Capricorn aims to acquire significant mi-nority stakes in start- and scale-ups. Its most recent fund (Capricorn Sustainable Chemistry Fund) invests in firms that answer to the need for novel feedstock, innovative & sustainable chemical processes, better functional materials, food & feed products, fibres and jet fuels.

10

CONTACT

The Sofinnova Industrial biotech 1 (IB1) fund is a 125M€ fund that was raised in 2017. We are investing in start-ups that position themselves in the field of the ecological transition of the broad chemical industry (from agrochemical to consumer products; chemicals in-cluding materials, intermediates …). We plan to invest in 8 to 10 companies both in Europe and North America.

Investment focus: We are early stage investors so we can invest as early as possible and as late as end of piloting/demonstration scale. We are interested in every venture that can help displace or replace use of fossil carbon by renewable carbon.

Sofinnova Partners

Mark RedshawInvestment Director · [email protected]

CONTACT

Michael KrelPrincipal, Industrial Biotechnology Funds · [email protected]

Evonik Venture Capital

Evonik Venture Capital is the corporate venture arm of Evonik Industries AG, one of the world’s leading providers of specialty chemicals. We make medium-term investments in start-ups and venture capital funds throughout the world.

Investment focus: We invest in young companies with innovative technology and high growth potential in the field of specialty chemicals, companies with solutions to problems within the following megatrends: resource efficiency, health & nutrition, globalization.

11

Start-up Profiles

12

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Abolis develops a portfolio of technologies to design, construct and scale up tailor-made bioprocesses for any arbitrary molecule in order to produce them using fermentation of renewable sugars. Abolis works in partnership with its customers from the chemical in-dustry and a network of collaborators to cover the entire development chain from the need of a given molecule to the delivery of the final process book.

Which market/clients do you address and which short-term/long-term goals do you have?Abolis already works in partnership with a pharmaceutical company and a medium-sized cosmetic ingredient producer. We aim at developing more deals in these two markets, as well as expanding applications in fine chemistry, nutraceuticals and bio-control applica-tions.

What makes your approach unique compared to other stakeholders in the field?Abolis is very experienced with design, implementation and optimization of long meta-bolic pathways. We have long experience in very complex polyphenol production using metabolic engineering. Abolis works with its partners using an agile, industrial Go/NoGo driven development plan.

Abolis Biotechnologies

Founded: 2014 Number of Employees: 20

Country: France

Investors: Medevice Capital, business angels

Market: fine chemistry, advanced chemicals, pharmaceutical intermediates and active substances,

nutraceutical, cosmetic industry and bio-control

Website: www.abolis.fr

Cyrille Pauthenier (CEO)[email protected] · +33 695 410 187

13

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Since July 2017, Algae Natural Food is developing a unique technology for the growth and industrial scale up of micro algae. Algae Natural Food provides natural products deriving from photosynthesis, able to deliver proteins and essential oils. Our solutions are driven by the reuse of existing value flows like process water, carbon dioxide or excess heat. This does not only reduce the cost for our production, but essentially contributes to improving the quality of living by an implemented circular economy.

Which market/clients do you address and which short-term/long-term goals do you have?The first targeted markets are neutraceuticals, food intrants and cosmetics. Algae Natural Food plans for a multiplication of plants copied on the model reached at Cargill Stras-bourg to service local customers. Eight additional projects are in study with SUEZ and two other partners. The objective is to produce 200tons/ha/year by 2020.

What makes your approach unique compared to other stakeholders in the field?The system is disrupting existing technologies, with productivity 16 times as high as current standard rates. A unique patented core of reactor allowing quality of microalgae production, together with full automatization. First collaboration with Cargill Strasbourg: Installed at Cargill’s Malt plant, the experienced synergies are nearly perfect. Algae Natural Food has a large benefit from Cargill’s process water and other supplies.

Algae Natural Food

Founded: 2014

Number of Employees: 11

Country: France

Investors: Francis Kurz, private investors

Market: pharmaceuticals and cosmetics, nutraceuticals, food-industry intrants, feed and pet-food

Website: www.algae-natural-food.com

Francis Kurz (CEO) | Solène Rivière Saali (Business & Product Development)[email protected] | [email protected]

14

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Algaepro AS will be producing microalgae based on CO2 captured from oil refineries and nutrient from fish farms. Energy will be captured from industrial process water. Algaepro wants to give a substantial contribution to the new circular bioeconomy.

Which market/clients do you address and which short-term/long-term goals do you have?The short-term goal is to set up a demo plant for automatic production of microalgae based on captured CO2, nitrogen and phosphorus from fish sludge and energy for indus-trial process water. The short-term market is a feed additive to cleanerfish, other marine finfish larval feed and shrimp larvae. The medium term goal is to start full scale production in a 34 ha farm and process the biomass for feed. The long-term goal is to start sea-based production of microalgae as feed additive and food.

What makes your approach unique compared to other stakeholders in the field?Algaepro has access to newly developed technologies, large quantities of CO2, process water and land. Large aquaculture feed producers are located less than one hr by car from the production site.

Algaepro AS

Founded: 2018

Country: Norway

Investors: Founders/employees Number of Employees: 4 (including consultants and founders)

Market: Special feed additives from aquaculture, focus on microalgae as a new source for marine fatty acids

like DHA and proteins

Website: www.algaepro.no

Ingmar Høgøy (Chairman of the board)[email protected] · +47 934 324 94

15

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Arbiom addresses the world’s growing nutritional needs by integrating a historically non-food, renewable carbon source (wood) into the food supply chain to produce proteins. Ar-biom helps solve the challenge of meeting global nutritional needs using less resources by producing a healthier, more sustainable protein source from wood. Arbiom’s technology platform will be deployed at industrial-scale to produce commercial quantities and relieve the ecological stresses of fish meal and soy.

Which market/clients do you address and which short-term/long-term goals do you have?Arbiom is targeting three markets based on the nutritional benefits and price-performance of SylPro: Salmonids, weanling pigs and companion animals. Arbiom is commercializing the technology thanks to the BBI-JU funded SYLFEED project, which assembles key play-ers in the wood to food value chain from five countries. One of the SYLFEED objectives is building a demonstration facility to produce multi-tons of product annually, starting in 2019 and guide the commercial-scale plant design, intended to be operational by the end of 2022. Arbiom is completing animal trials over 2018–2019.

What makes your approach unique compared to other stakeholders in the field?Future fish meal shortages, price volatility and biodiversity loss are driving the aquaculture industry to look for feed based on alternative protein sources. Our wood to food approach is unique and compared to soy meal provides a more nutritional, economical, traceable & sustainable protein source for animal health.

Arbiom

Founded: 2014

Number of Employees: 30+

Country: USA (HQ) and France

Investors/Supporters: BBI-JU project SYLFEED

Market: Protein-rich ingredients for feed and food markets in animal health based on wood as a resource

Website: www.arbiom.com

EUROPE: Amélie Drouault (Partnerships Manager) · [email protected]: Emily Glenn (Business Development Manager) · [email protected]

16

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Our technology enables the establishment of the bioeconomy and thus, it relieves the bio-based economy from its dependency on sugars or plant-derived feedstocks. We will set up a bioeconomy on abundant feedstocks such as CO2 and water. Through CO2-electrolyzers CO2 is reduced to a formate, which is a liquid and is storable. Formate is the feedstock for our bioprocess which can be directed into different products by applying synthetic biology.

Which market/clients do you address and which short-term/long-term goals do you have?b.fab addresses customers in the chemical, cosmetics and oil industry. We want to pro-vide new economical and sustainable routes to produce chemicals starting from CO2, wa-ter and renewable energy. Our goal is to establish a Formate Bioeconomy which is based on artificial photosynthesis and synthetic biology enabling better energy efficiencies in converting solar energy into products. Synthetic pathway design allows us to adapt our cell factories for production of bioplastics, solvents and terpenes.

What makes your approach unique compared to other stakeholders in the field?b.fab’s bioprocesses are unique in terms of energy efficiency from solar energy to product. At the same time, we use liquid, storable C1 feedstocks to feed our bioprocesses and thus, we overcome common mass transfer limitations of gas fermentations. Additionally, b.fab applies aerobic cell factories which can be easily designed, handled and optimized to en-sure a fast bioprocess development and industrial implementation.

b.fab GmbH

Founded: 2018


Country: Germany

Investors: b.value AG

Market: Biopolymers, biosolvents, biooils, feed additives.

Website: www.bfab.bio

Dr.-Ing. Frank Kensy (Managing Director)[email protected] · +49 231 550 337 70

17

CONTACT

Which input does your business/core technology provide towards a bio-based economy?The solution of BES Europe Ltd. is able to facilitate circular solutions in wastewater treat-ment, and remote, online sensing of organic content and toxicity, to provide smart sen-sors and solutions for the future bio-based industries (for instance, to fermentation in-dustries).

Which market/clients do you address and which short-term/long-term goals do you have?Now, the target market is the wastewater treatment sector including plant operators, in-frastructure developers and bio-based industries with high organic content effluent. Our solution measures and tracks BOD level through the process. In the long-term, we aim to to develop biosensor networks for district, smart cities and natural water bodies and river basins - even selectively for specific compounds.

What makes your approach unique compared to other stakeholders in the field?BES Europe Ltd. is developing biosensors with novel designs based on microbes which provide the signal directly, not relying on precious instruments subjected to the harsh con-ditions of wastewater. Current methods are based on sampling and timely lab work, while we deliver online and remote results within a few hours. The development is supported by recognized academic and industrial partners.

BES Europe Ltd.


Country: Hungary

Investors/Supporters: Climate-KIC, MVM Edison and EIT InnoEnergy;

Hungarian Government via ESIF; PANNON Pro Innovations Ltd.

Market: Wastewater treatment and biosensors markets for smart cities

Website: www.bes-water.com

Gábor Máté Erdő (CEO)[email protected]

18

CONTACT

Which input does your business/core technology provide towards a bio-based economy?BioBTX will provide the technology to produce sustainable aromatics such as BTX, either from liquid or solid biomass, or from end-of-life materials, like plastic mixtures or compos-ites, thus allowing the closure of the circular economy.

Which market/clients do you address and which short-term/long-term goals do you have?BioBTX serves the chemicals and polymers market with benefits for brand owners to have fully bio-based products. The first goal is to demonstrate technology and deliver products on pilot plant scale. The next phase will be demo scale.

What makes your approach unique compared to other stakeholders in the field?BioBTX technology is highly flexible in feedstock choice, has a much lower CO2 footprint than fossil based products, provides drop-in (now sustainable) chemicals, is an integra-tion of known, scalable processes and minimizes catalyst deactivation.

BioBTX B.V.


Country: The Netherlands

Investors: Carduso Capital B.V., Blue Sky Holding B.V., T.R.de Vries Beheer B.V., KNN Groep B.V., Flohr Beheer B.V.

Market: Platform chemicals, i.c. BTX, aromatics, specifically bio-based or renewable aromatics, main industry

applications include polymers, intermediate chemicals, solvents, fuels

Website: www.biobtx.com

Pieter Imhof (CEO)[email protected] · +31 651 521 179

19

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Current methods to produce our compounds rely on chemical synthesis which are costly and toxic. BFC breakthrough technology utilises bio-production to synthesize and bring down the cost and toxicity, rather than by chemical synthesis from non-renewable material.

Which market/clients do you address and which short-term/long-term goals do you have?Our compounds and derivatives are used in many industries such as cosmetics, textiles, laboratory research, drug development and decontamination. Our first goal is to become the first supplier of phosphorylated compounds and derivatives of the pharmaceutical industry.

What makes your approach unique compared to other stakeholders in the field?BFC will use a unique own developed bio-production strategy (BFC exclusive Patent), to produce a platform molecule through a genetically engineered bacteria. This solution will bring many compounds to a low market price/high margin and open attractive markets.

Biotech Fine Chemical France

Founded: 2016


Country: France

Investors: Co-founders

Market: Fine chemicals, phosphorylated compounds and API’s

Website: www.bfcfrance.com

Christopher Lang (CEO)[email protected]

BIOTECHFINECHEMICALFRANCE

20

CONTACT

Which input does your business/core technology provide towards a bio-based economy?BlueGene’s speciality is developing unique microbial strains and technologies for bio-con-versions of low-cost starting compounds to high-value chemicals. BlueGene’s vision is to replace existing bulk industrial chemical production methods with efficient, environmentally safe bio-conversions that avoid the use of toxic chemicals, prevent formation of unwanted side-products and reduce waste. Our slogan is “Blue Genes, Green Technologies”.

Which market/clients do you address and which short-term/long-term goals do you have?Textile manufacturers and dyers, hair dye manufacturers, fine chemicals suppliers. Short-term goal is to scale-up production to supply materials to identified end users. Long-term is to scale production and develop an international reputation in production of green chemicals and bio-organic textile dyes.

What makes your approach unique compared to other stakeholders in the field?Application of synthetic biology, bioinformatics and advanced molecular biology know-how to construct versatile and robust microbial bioconversion strains. Unique product range and stability.

BlueGene Technologies Ltd

Founded: 2015


Country: United Kingdom

Investors/Supporters: Imperial College Incubator

Market: Textile manufacturing and dyeing industries, cosmetics-hair colourants, food colourants, fine chemicals

Website: www.synbicite.com/collaboration/Partners/bluegene-technologies-ltd/

Stan Theophilou, Ph.D (Director and Chief Scientist)[email protected] · +44 207 482 1244 (T) · +44 758 342 33 35 (M)

21

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Our sugar substitutes are made using cheap and abundant plant material. This means that they can be sustainably produced, contributing towards a bio-based economy.

Which market/clients do you address and which short-term/long-term goals do you have?We address all businesses aiming to reduce the sugar content of their food products, with an initial focus on bakery segments. In the short-term, we aim to sell to restaurants. In the long-term, our goal is to supply multinational food manufacturing companies to enable sugar reduction in mainstream food products.

What makes your approach unique compared to other stakeholders in the field?Current bulking sweeteners are more expensive than sugar on a weight-per-weight basis. Our sugar substitutes are forecast to meet cost parity with sugar at scale, removing the economic barrier to reducing sugar in mainstream food products.

Cambridge Glycoscience Inc.



Investors: Y Combinator, Felicis Ventures, Global Founders Capital,

Romulus Capital, DCVC, Western Technology Investments

Market: Sugar in the manufactured food industry

Website: https://camglyco.com/

Ruben Tadmor (COO)[email protected] · +44 740 061 03 21

22

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Currently, natural food colorants are produced via extraction from fruits and vegetables, which alternatively could be used as food. Their production is not only dependent on the availability of the extraction source but also on existing farming space. Our red colorant ChromoRed is produced by a wild-type filamentous fungus in a fermentation set-up. Our production process is more sustainable since neither food resources nor farming space are required.

Which market/clients do you address and which short-term/long-term goals do you have?In 2023, the global market of natural food colorants is expected to have a value of 3 bil. USD, of which more than 50% are red. Chromologics aims at replacing the red colorant carmine in current food applications. The current carmine market is estimated to be 420M USD (projection 2023: 560M USD). Carmine is currently used in beverages, dairy, meat and confectionary.

What makes your approach unique compared to other stakeholders in the field?With ChromoRed, Chromologics aims to replace carmine in current food applications. The current European carmine market has a value of 150M USD. Carmine struggles with poor consumer reputation since it does not comply with special dietary requirements like vegan, halal, and kosher, and has been associated with allergies. After 6–8 years of EFSA approval of ChromoRed we aim at taking 10% of the market share of carmine in meat, dairy and confectionary applications.

Chromologics


Country: Denmark

Investors: Non-dilutive pre-seed investments from the Novo Nordisk

Foundation, Innovation Foundation Denmark and the Technical University of Denmark

Market: Natural colorants with special focus on natural food colorants

Website: www.chromologics.com

Gerit Tolborg (CEO)[email protected] · +45 616 032 09

23

CONTACT

Which input does your business/core technology provide towards a bio-based economy?DAB enables the bio-based economy. Bio-based initiatives often struggle with setting their product price competitively in the market. DAB’s Fermentation Acceleration and Separa-tion Technology (FAST) is the boost solution to common issues in industrial biotechnolo-gy like low productivity by product inhibition. It can help reduce investment costs and high separation costs. By combining fermentation and separation in one continuous in-situ re-moval production system, we reduce operational costs by up to 50%. Our business model is to team up with CMO’s for speciality chemicals and to demonstrate our technology at scale in a dedicated consortium and then further out-licence the mature technology.

Which market/clients do you address and which short-term/long-term goals do you have?Producing bio-based products in a cost effective way demands the best of every aspect of the production process: cheap and readily available feedstock, optimized strains, effec-tive fermentation and separation technologies, healthy distribution agreements and more. Quite a lot for one single company, big or small. Therefore, DAB believes that building con-sortia is the way to go for industrial biotech stakeholders. DAB and its owners are actively looking to participate in and help building consortia. Our target is to expand our portfolio and to retrofit a first production plant in 2020.

What makes your approach unique compared to other stakeholders in the field?DABs integrated design approach is unique and our solution is scalable a tailor-made inte-grated bioreactor or flexible add-on solution to an existing fermentation plant.

Delft AdvancedBiorenewables (DAB)

Founded: 2012



Investors: Delft University of Technology and private investor

Market: Bioprocessing for speciality chemicals

Website: http://delftab.com

Kirsten Herben-Steinbusch (CEO) [email protected]

24

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Enzymes and natural proteins have great potential in many sectors, including food, bever-ages, pharma, animal feed, textile processing, laundry detergents and many more. How-ever, they are often not ideal for industrial use because of its limitations with regard to stability or efficiency. Our technology enables the creation of optimized enzymes and pro-teins for specific industrial needs.

Which market/clients do you address and which short-term/long-term goals do you have?Enantis’ pipeline focuses on molecules for pharma applications. Also we have ongoing projects for high-performing enzymes for animal feed and synthetic biology. Our short-term goal is to find partners for the commercialization of our products, while in the long term we would like to expand in the sector of natural proteins for food, beverages, textile processing, laundry detergents and many more.

What makes your approach unique compared to other stakeholders in the field?Enantis’ unique value is our rapid automated workflow for the in silico design of mutant proteins that combines energy- and evolution-based predictions for reliable design of sta-ble multiple-point mutants. In contrast to other in silico approaches that usually predict only single-point mutations, we are able to reliably design stable multi-point mutants, with a success rate exceeding 60%.

Enantis s.r.o.


Country: Czech Republic

Investors/Supporters: Horizon2020 SME funding, Technology Agency of

the Czech Republic, ES-Cat Marie Curie Initial Training Network, Rafts4Biotech

Market: High-performing proteins, enzymes or APIs used in the cosmetics, pharma or animal feed sector

Website: www.enantis.com

Marco Minoia (Business Development Manager) [email protected] · +420 776 804 793

Enantis

25

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Evologic Technologies is producing a symbiotic fungus as seed coating, to help farmers over the world grow more with less fertilizer. Thereby this natural fungus greatly helps to increase sustainability in agriculture. Moreover, our core technology of producing hairy roots in a bioreactor allows us to produce secondary plant metabolites (complex chemical molecules) non-GMO in a bioprocess rather than by chemical synthesis.

Which market/clients do you address and which short-term/long-term goals do you have?Evologic targets the biostimulant market, with a current volume of 1.5 bn and growing by 11% per year. Our clients are seed distributors which receive our fungi formulation to coat their seeds prior to distribution to the farmers. This allows a high-quality seed coating pro-cess and consequently facilitates high efficiency of the fungi. Within the next 24 months we are planning to reach our final cost of goods and target to start selling our product. Our long-term goal is to become one of the leading providers for high quality biostimulants for seed coating.

What makes your approach unique compared to other stakeholders in the field?The production approach of Evologic Technologies for this symbiotic fungus is unique. No competitor worldwide has succeeded in producing this fungus in a scalable bioprocess. Moreover, our application is unique, instead of supplying farmers directly for an in-furrow application, we supply seed distributors with the seed coating to ensure a high-quality product application.

Evologic Technologies


Country: Austria

Investors: BayWa, Raiffeisen Waren Austria,

Fritz Mauthner Handelsgesellschaft m.b.H. & Co. KG, Vivida Beteiligungsgesellschaft GmbH

Market: Crop protection market with a focus on biostimulants and seed coating agents

Website: www.greenspot-tech.com

Wieland Reichelt (CEO)[email protected] · +43 650 840 30 15

26

CONTACT

Green Spot Technologies

Founded: 2016 in NZ, 2018 in France


Country: France

Investors: French-based angel investors

Market: Low-calorie food, functional flours, gluten-free, and dietary supplements

Website: www.greenspot-tech.com

Which input does your business/core technology provide towards a bio-based economy?Our technology is based on the bioconversion of sugars and plant polymers from various fruit and vegetable by-products from the juice and beverages industry into nutritious (com-plete) protein using a proprietary fermentation process, and then dried and milled to form ingredients with flour type consistencies. Thus, the only real “waste” is water vapour that is released during the drying process (which still can be recovered).

Which market/clients do you address and which short-term/long-term goals do you have?Compared to alternative food ingredients based on milk, egg, starch‐rich or gluten‐contain-ing plants (e.g. soy/wheat/pea) Green Spot’s fermented flours offer a unique natural com-bination of low “carb”, low fat, high-fibre and high-protein within a single ingredient, add-ing further benefits such as higher content of prebiotic beta-glucan fibres and minerals. In addition, it offers better properties for food technologist. We have a focus on low carb and dietary products such as bakery goods, breakfast meals, savoury and sweet snacks, smoothies and healthy drinks. Our low “carb” flours could also replace high “carb” flours in pizza bases and pastas.

What makes your approach unique compared to other stakeholders in the field?The production of Green Spot’s fermented flours is environmentally responsible, as it uses food substrates that are usually wasted in a waste-free process, requiring little to no addi-tional resources. Competitor products often consume large amounts of water and land for their production.

Silas Villas-Boas (Director, CEO)[email protected] · +64 217 599 69

27

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Biomimetics - copying structural colour from bacteria into iridescent materials to replace/disrupt the less sustainable pigment/dyes used now.

Which market/clients do you address and which short-term/long-term goals do you have?B2B - help manufactuers of coloured products via licensing agreements.

What makes your approach unique compared to other stakeholders in the field?Development of genetics of structural colour in bacteria to “create new coloured materials.”

Hoekmine B.V.

Founded: 2016



Investors: Founders

Market: Colour (paint, clothing, cosmetics)

Website: www.hoekmine.com

Dr Colin Ingham (CEO)[email protected]

28

CONTACT

Which input does your business/core technology provide towards a bio-based economy?Our technology reduces the cost of lipids produced by fermentation, and for our first product, biosurfactants, it makes them cost-competitive with synthetic surfactants on the market.

Which market/clients do you address and which short-term/long-term goals do you have?We can immediately provide our integrated production technology to companies looking to reduce production cost for sophorolipids by tripling output compared to state of the art. We provide a platform solution for the production of biosurfactants through a collabora-tion of world leading experts and manufacturers. We can apply our technology to other lipids produced by fermentation in collaboration with other production companies.

What makes your approach unique compared to other stakeholders in the field?We focus on providing process engineering technologies for integrated production and separation, rather than producing the biosurfactants ourselves, or developing application technology. This has enabled us to increase the overall output of a given bioreactor x3-4. We collaborate with market leaders to provide a complete platform solution for biosurfac-tant production.

Holiferm Ltd.

Founded: 2018



Investors: n/a

Market: Surfactants, personal care, cosmetics, oil field chemicals, agriculture.

Website: www.holiferm.com

Ben Dolman (CEO)[email protected] · +44 779 149 70 29

29

CONTACT

Which input does your business/core technology provide towards a bio-based economy?We provide services for R&D projects of biotechnology companies. We help during the design phase of biosolutions. Our technology, based on virtual organisms, mimics in silico experimental processes. Thus, we accelerate R&D processes by reducing wet phase, we secure R&D output by avoiding dead-end solutions, we drive the R&D processes toward patentable products within bioeconomy.

Which market/clients do you address and which short-term/long-term goals do you have?In the short-term, we propose services to design synthetic organisms for industrial mi-crobiology. We developed our “tracker” AI algorithm and performed a convincing proof of concept in designing methylotrophs organisms. In the long-term, we are developing a prototype of virtual crop selection process for breeding companies. We aim to validate the prototype within two years.

What makes your approach unique compared to other stakeholders in the field?Behavior of our virtual organisms relie on causal mechanisms within complex molecular networks of living cells. Although metabolic network modelling is commonly optimised, we are experts in including and designing regulatory modules. Our crop virtual selection service is without equivalent in the world by combining quantitative genetics methods with systems biology methods.

iMEAN

Founded: 2018


Country: France

Investors: Love money

Market: Synthetic biology & bioprocessing for R&D; agriculture

Website: www.imean-biotech.com

Rémi Peyraud (CEO)[email protected] · +33 786 833 945

30

CONTACT

Which input does your business/core technology provide towards a bio-based economy?We are converting the waste of the most popular and wasteful yet magical plant on earth: coffee. By upcycling this waste into different high-quality, cost-competitive active ingredi-ents, we are accelerating the transition to a more bio-based and healthier society.

Which market/clients do you address and which short-term/long-term goals do you have?Cosmetic, nutraceutical, and food manufacturers. Short-term goal is to establish Scandi-navia’s first coffee biorefinery. In the long-term, through joint ventures, we hope to estab-lish more biorefinieries in the US, Europe and Asia.

What makes your approach unique compared to other stakeholders in the field?We are the first company to create a fully circular economy around coffee. We are also the first company in the world to focus on exploiting coffee waste as an unusual but sustain-able health elixir and finally break the myth that coffee is bad for your health (It’s the opp-posite!) meanwhile helping coffee farmers back in Colombia, in these tough times for the industry due to record low coffee prices and global warming. Currently, other companies recycling coffee waste focus more on fertilizers, biofuels, or pellets.

Kaffe Bueno ApS.

Founded: 2017


Country: Denmark

Investors: Capnova (PreSeed)

Market: Cosmetics, nutraceuticals and functional food/beverages ingredients

Website: www.kaffebueno.com/

Juan Pablo Medina (CEO)[email protected] · +45 713 397 59

31

CONTACT

Which input does your business/core technology provide towards a bio-based economy?As a plant cell, moss can produce most of the plant-derived compounds with little bioengi-neering. One distinct characteristic of moss is that it has a very low fragrance background that does not interfere fragrance when produced. Likewise, the company was established to sell fragrant moss as a living air freshener in the USA. Now, we are focusing on entering the fragrance industry by improving our moss lines.

Which market/clients do you address and which short-term/long-term goals do you have?Currently, we sell our product – fragrant moss – in the US market. This will generate rev-enue that will drive or support us to enter the fragrance industry in the long-term. Our short-term goal is to have stable revenue from the fragrant moss for the next three years. Based on this business, we will commercialize purified fragrance products in the European market in the long-term.

What makes your approach unique compared to other stakeholders in the field?Using plant cells for the production makes our approach unique. To date, most of the bio-based chemicals are produced from microbes. We are aware that the production ef-ficiency in microbes is much higher, but some of the plant-derived compounds – those that are toxic to the microbes – are still hard to produce from them. Likewise, we aim to produce the type of niche compounds that plant cells can do better.

Mosspiration Biotech IVS

Founded: 2016


Country: Denmark

Investors: Innovation Fund Denmark, Korea Institute of Startups & Entrepreneurship Development (KISED)

Market: Air freshener (in USA), fragrance industry (perfume material)

Website: www.mosspirationbiotech.com

Hansol Bae (CSO)[email protected] · +45 239 346 16

32

CONTACT

Which input does your business/core technology provide towards a bio-based economy?PHYTOLINC aims to make microalgae production economic and ecologically sustainable to benefit from the great potential of algal products. The team is developing an innovative photobioreactor for microalgae production. The used membrane system enables highly ef-ficient cultivation as well as the production of new algae species. We develop a modular system for aquaculture and aquaponics purposes, as well as microalgae mass production.

Which market/clients do you address and which short-term/long-term goals do you have?We address aquaculture firms as well as microalgae producers. With our photobioreactor, we enable hatcheries to extend their feed spectrum with further algae species containing e.g. very long unsaturated fatty acids. Also, we enable microalgae producers to grow new algae species which are exceptionally rich in e.g. Omega 3 & 6 or consist of valuable pig-ments. Currently, we are upscaling the lab-scale prototype to industrial scale and will have completed the construction of our new prototype by the end of 2018.

What makes your approach unique compared to other stakeholders in the field?Current closed photobioreactors are water-filled tubular or flat panel systems. Due to arising shear forces, many high-value algae species do not grow in these systems. PHYTOLINC enables water separated algae cultivation. Thanks to the innovative mem-brane system, the algae cells grow immobilized, attached to a membrane. This results in more efficient lighting, a better CO2 supply and higher growth rates. Also, we avoid shear forces and enable the production of new algae species.

PHYTOLINC


Country: Germany

Investors/Supporters: Funded by the start-up program EXIST of the German Federal Ministry for Economic

Affairs and Energy

Market: Aquaculture, microalgae, food

Website: Coming soon – www.phytolinc.com

Arne Maercker (Co-Founder)[email protected] · +49 178 188 98 24

33

CONTACT

Which input does your business/core technology provide towards a bio-based economy?PILI proposes a competitive alternative to the 1.8Mt petrochemical textile dyes market (€8bn) through the production of bio-based products.

Which market/clients do you address and which short-term/long-term goals do you have?We address first of all the market of textile dyes. We aim at validating two ranges of prod-ucts in 2019 and start our industrialization in 2021.

What makes your approach unique compared to other stakeholders in the field?None of the current actors on the textile dyes sector are involved in biotechnology. Among other biotech companies, PILI differentiates through a market-pull approach mimicking existing products.

PILI Inc.

Founded: 2015


Country: France

Investors: SOSV, FASHION FOR GOOD, WISEED

Market: Textile dyes, organic pigments

Website: www.pili.bio

Jérémie Blache (CEO)[email protected] · +33 632 157 993

34

CONTACT

Which input does your business/core technology provide towards a bio-based economy?The Plantics-GX resin and technology could significantly contribute to the bio-based economy, as it is a potential game changer in the multibillion market of thermoset resins. Toxic, flammable, and fossil based thermoset resins are currently used in this market (e.g. polyurethane and phenol formaldehyde resins). Besides replacement of existing thermo-set resins it also creates the opportunity for 100% bio-based and recyclable construction materials with (local) natural materials such as hemp and flax. Although recycling is pre-ferred, if Plantics-GX enters the environment it is biodegradable.

Which market/clients do you address and which short-term/long-term goals do you have?Market: Construction, furniture, and horticulture market. Approach: We currently co-de-velop 3-4 product market applications (binder, foam, composite) with strong (market) partners and create and share value together. Targets: 2018 functionality of two PMC’s proven and one PMC introduced in the market. 2019 functionality of 3-4 PMC’s proven and two PMC’s introduced in market. 2022 break even, development and commercialization of more product market combinations.

What makes your approach unique compared to other stakeholders in the field?New and unique ‘green’ thermoset product portfolio. The only 100% bio-based thermoset resin in the market. Safe: formaldehyde and MDI free, no other toxic components, no “plas-tic soup”, low CO2 footprint, flame-retardant. IP protected in EU, US, China.

Plantics B.V.

Founded: 2014



Investors: Management Plantics, other private investors, and University of Amsterdam Ventures

Market: Green and safe thermoset resin applications in a/o the construction, furniture, and horticulture markets

Website: www.plantics.com

Wridzer Bakker (CEO)[email protected] · +31 651 187 533

35

CONTACT

SilicoLife Lda.

Founded: 2010


Country: Portugal

Investors/Supporters: SME instrument of EC

Market: Industrial biotechnology, feed & food, pharma, renewable chemicals

Website: www.silicolife.com

Which input does your business/core technology provide towards a bio-based economy?SilicoLife designs optimized microorganisms and novel pathways for industrial biotech-nology applications, based on artificial intelligence and metabolic engineering approach-es, for the sustainable production of specific target compounds such as chemicals, food ingredients or biopolymers. SilicoLife’s input to the bio-based economy translates into al-ternative bio-based processes for the production of compounds currently achieved only via chemical synthesis or limited to plant extraction.

Which market/clients do you address and which short-term/long-term goals do you have?After more than eight years working closely with leading industrial players, we are now extending our activities from the computational design of cell factories to the integrated development of optimized strains, focusing on the creation of biological alternatives for the production of high value chemicals that can benefit from being produced using fer-mentative processes, tackling high value applications as pharma and F&F.

What makes your approach unique compared to other stakeholders in the field?SilicoLife’s approach is distinct as it uses de-risked selection of targets and rational design methodologies, taking advantage of the latest advances in AI in combination with biologi-cal knowledge. This approach is focused on attacking molecule families in an incremental fashion, reducing the risk of failed attempts by providing valuable alternatives, contribut-ing to the generation of IP from a very early stage.

Simão Soares CEO [email protected] · +35 1 965 221 885

www.efibforum.com

1096513 EFIB 2018 Start-up-Village Broschur · 2019-07-29 · Organised by Start-up Village @EFIB...

Documents

Transcript of 1096513 EFIB 2018 Start-up-Village Broschur · 2019-07-29 · Organised by Start-up Village @EFIB...